Axsome Therapeutics AXSM Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's additional paid-in capital?
- Axsome Therapeutics (AXSM) reported additional paid-in capital of $1.43B in Q1 2026.
- How has Axsome Therapeutics's additional paid-in capital changed year-over-year?
- Axsome Therapeutics's additional paid-in capital increased by 15.4% year-over-year, from $1.24B to $1.43B.
- What is the long-term trend for Axsome Therapeutics's additional paid-in capital?
- Over 5 years (2020 to 2025), Axsome Therapeutics's additional paid-in capital has grown at a 28.8% compound annual growth rate (CAGR), from $392.59M to $1.39B.
- What does additional paid-in capital mean?
- The amount of capital raised from investors above the par value of the stock.
- How do you interpret additional paid-in capital?
- An increase indicates successful equity financing rounds or the exercise of employee stock options.
- How does additional paid-in capital compare across companies?
- Commonly high in growth-stage biotech companies relying on equity markets for funding.